The Middle East Respiratory Syndrome (MERS)
Identifieur interne : 001345 ( Pmc/Corpus ); précédent : 001344; suivant : 001346The Middle East Respiratory Syndrome (MERS)
Auteurs : Esam I. Azhar ; David S. C. Hui ; Ziad A. Memish ; Christian Drosten ; Alimuddin ZumlaSource :
- Infectious Disease Clinics of North America [ 0891-5520 ] ; 2019.
Abstract
The Middle East respiratory syndrome (MERS) is a novel lethal zoonotic disease of humans caused by the MERS coronavirus (MERS-CoV). Although MERS is endemic to the Middle East, travelers have exported MERS-CoV on return to their home countries. Clinical manifestations range from mild to severe acute respiratory disease and death. The elderly, immunocompromised, and those with chronic comorbid liver, lung, and hepatic conditions have a high mortality rate. There is no specific treatment. Person-to-person spread causes hospital and household outbreaks, and thus improved compliance with internationally recommended infection control protocols and rapid implementation of infection control measures are required.
Url:
DOI: 10.1016/j.idc.2019.08.001
PubMed: 31668197
PubMed Central: 7127753
Links to Exploration step
PMC:7127753Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Middle East Respiratory Syndrome (MERS)</title><author><name sortKey="Azhar, Esam I" sort="Azhar, Esam I" uniqKey="Azhar E" first="Esam I." last="Azhar">Esam I. Azhar</name><affiliation><nlm:aff id="aff1">Special Infectious Agents Unit, King Fahd Medical Research Centre, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Hui, David S C" sort="Hui, David S C" uniqKey="Hui D" first="David S. C." last="Hui">David S. C. Hui</name><affiliation><nlm:aff id="aff2">Department of Medicine and Therapeutics, Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong</nlm:aff></affiliation></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A." last="Memish">Ziad A. Memish</name><affiliation><nlm:aff id="aff3">College of Medicine, Alfaisal University, Riyadh, Saudi Arabia</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Infectious Diseases Division, Department of Medicine and Research, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name><affiliation><nlm:aff id="aff5">Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany</nlm:aff></affiliation></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:aff id="aff6">Center for Clinical Microbiology, University College London, Royal Free Campus 2nd Floor, Rowland Hill Street, London NW3 2PF, United Kingdom</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31668197</idno><idno type="pmc">7127753</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127753</idno><idno type="RBID">PMC:7127753</idno><idno type="doi">10.1016/j.idc.2019.08.001</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">001345</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001345</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The Middle East Respiratory Syndrome (MERS)</title><author><name sortKey="Azhar, Esam I" sort="Azhar, Esam I" uniqKey="Azhar E" first="Esam I." last="Azhar">Esam I. Azhar</name><affiliation><nlm:aff id="aff1">Special Infectious Agents Unit, King Fahd Medical Research Centre, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Hui, David S C" sort="Hui, David S C" uniqKey="Hui D" first="David S. C." last="Hui">David S. C. Hui</name><affiliation><nlm:aff id="aff2">Department of Medicine and Therapeutics, Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong</nlm:aff></affiliation></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A." last="Memish">Ziad A. Memish</name><affiliation><nlm:aff id="aff3">College of Medicine, Alfaisal University, Riyadh, Saudi Arabia</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Infectious Diseases Division, Department of Medicine and Research, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Drosten, Christian" sort="Drosten, Christian" uniqKey="Drosten C" first="Christian" last="Drosten">Christian Drosten</name><affiliation><nlm:aff id="aff5">Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany</nlm:aff></affiliation></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:aff id="aff6">Center for Clinical Microbiology, University College London, Royal Free Campus 2nd Floor, Rowland Hill Street, London NW3 2PF, United Kingdom</nlm:aff></affiliation></author></analytic><series><title level="j">Infectious Disease Clinics of North America</title><idno type="ISSN">0891-5520</idno><idno type="eISSN">1557-9824</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The Middle East respiratory syndrome (MERS) is a novel lethal zoonotic disease of humans caused by the MERS coronavirus (MERS-CoV). Although MERS is endemic to the Middle East, travelers have exported MERS-CoV on return to their home countries. Clinical manifestations range from mild to severe acute respiratory disease and death. The elderly, immunocompromised, and those with chronic comorbid liver, lung, and hepatic conditions have a high mortality rate. There is no specific treatment. Person-to-person spread causes hospital and household outbreaks, and thus improved compliance with internationally recommended infection control protocols and rapid implementation of infection control measures are required.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Who" uniqKey="Who">WHO</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author><author><name sortKey="Hui, D S" uniqKey="Hui D">D.S. Hui</name></author><author><name sortKey="Perlman, S" uniqKey="Perlman S">S. Perlman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arabi, Y M" uniqKey="Arabi Y">Y.M. Arabi</name></author><author><name sortKey="Balkhy, H H" uniqKey="Balkhy H">H.H. Balkhy</name></author><author><name sortKey="Hayden, F G" uniqKey="Hayden F">F.G. Hayden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name></author><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name></author><author><name sortKey="Bestebroer, T M" uniqKey="Bestebroer T">T.M. Bestebroer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Who" uniqKey="Who">WHO</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alanazi, K H" uniqKey="Alanazi K">K.H. Alanazi</name></author><author><name sortKey="Killerby, M E" uniqKey="Killerby M">M.E. Killerby</name></author><author><name sortKey="Biggs, H M" uniqKey="Biggs H">H.M. Biggs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oh, M D" uniqKey="Oh M">M.D. Oh</name></author><author><name sortKey="Choe, P G" uniqKey="Choe P">P.G. Choe</name></author><author><name sortKey="Oh, H S" uniqKey="Oh H">H.S. Oh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oh, M D" uniqKey="Oh M">M.D. Oh</name></author><author><name sortKey="Park, W B" uniqKey="Park W">W.B. Park</name></author><author><name sortKey="Choe, P G" uniqKey="Choe P">P.G. Choe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kang, C K" uniqKey="Kang C">C.K. Kang</name></author><author><name sortKey="Song, K H" uniqKey="Song K">K.H. Song</name></author><author><name sortKey="Choe, P G" uniqKey="Choe P">P.G. Choe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hui, D S" uniqKey="Hui D">D.S. Hui</name></author><author><name sortKey="Azhar, E I" uniqKey="Azhar E">E.I. Azhar</name></author><author><name sortKey="Kim, Y J" uniqKey="Kim Y">Y.J. Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Who" uniqKey="Who">WHO</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reusken, C B" uniqKey="Reusken C">C.B. Reusken</name></author><author><name sortKey="Haagmans, B L" uniqKey="Haagmans B">B.L. Haagmans</name></author><author><name sortKey="Muller, M A" uniqKey="Muller M">M.A. Müller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reusken, C B" uniqKey="Reusken C">C.B. Reusken</name></author><author><name sortKey="Farag, E A" uniqKey="Farag E">E.A. Farag</name></author><author><name sortKey="Jonges, M" uniqKey="Jonges M">M. Jonges</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Drosten, C" uniqKey="Drosten C">C. Drosten</name></author><author><name sortKey="Kellam, P" uniqKey="Kellam P">P. Kellam</name></author><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Conzade, R" uniqKey="Conzade R">R. Conzade</name></author><author><name sortKey="Grant, R" uniqKey="Grant R">R. Grant</name></author><author><name sortKey="Malik, M R" uniqKey="Malik M">M.R. Malik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Doremalen, N" uniqKey="Van Doremalen N">N. van Doremalen</name></author><author><name sortKey="Bushmaker, T" uniqKey="Bushmaker T">T. Bushmaker</name></author><author><name sortKey="Munster, V J" uniqKey="Munster V">V.J. Munster</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ommeh, S" uniqKey="Ommeh S">S. Ommeh</name></author><author><name sortKey="Zhang, W" uniqKey="Zhang W">W. Zhang</name></author><author><name sortKey="Zohaib, A" uniqKey="Zohaib A">A. Zohaib</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liljander, A" uniqKey="Liljander A">A. Liljander</name></author><author><name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name></author><author><name sortKey="Jores, J" uniqKey="Jores J">J. Jores</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author><author><name sortKey="Mishra, N" uniqKey="Mishra N">N. Mishra</name></author><author><name sortKey="Olival, K J" uniqKey="Olival K">K.J. Olival</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name></author><author><name sortKey="Ithete, N L" uniqKey="Ithete N">N.L. Ithete</name></author><author><name sortKey="Richards, L R" uniqKey="Richards L">L.R. Richards</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sikkema, R S" uniqKey="Sikkema R">R.S. Sikkema</name></author><author><name sortKey="Farag, E A" uniqKey="Farag E">E.A. Farag</name></author><author><name sortKey="Himatt, S" uniqKey="Himatt S">S. Himatt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Azhar, E I" uniqKey="Azhar E">E.I. Azhar</name></author><author><name sortKey="El Kafrawy, S A" uniqKey="El Kafrawy S">S.A. El-Kafrawy</name></author><author><name sortKey="Farraj, S A" uniqKey="Farraj S">S.A. Farraj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author><author><name sortKey="Cotten, M" uniqKey="Cotten M">M. Cotten</name></author><author><name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Al Hammadi, Z M" uniqKey="Al Hammadi Z">Z.M. Al Hammadi</name></author><author><name sortKey="Chu, D K" uniqKey="Chu D">D.K. Chu</name></author><author><name sortKey="Eltahir, Y M" uniqKey="Eltahir Y">Y.M. Eltahir</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arwady, M A" uniqKey="Arwady M">M.A. Arwady</name></author><author><name sortKey="Alraddadi, B" uniqKey="Alraddadi B">B. Alraddadi</name></author><author><name sortKey="Basler, C" uniqKey="Basler C">C. Basler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Al Abdallat, M M" uniqKey="Al Abdallat M">M.M. Al-Abdallat</name></author><author><name sortKey="Payne, D C" uniqKey="Payne D">D.C. Payne</name></author><author><name sortKey="Alqasrawi, S" uniqKey="Alqasrawi S">S. Alqasrawi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garbati, M A" uniqKey="Garbati M">M.A. Garbati</name></author><author><name sortKey="Fagbo, S F" uniqKey="Fagbo S">S.F. Fagbo</name></author><author><name sortKey="Fang, V J" uniqKey="Fang V">V.J. Fang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Assiri, A" uniqKey="Assiri A">A. Assiri</name></author><author><name sortKey="Mcgeer, A" uniqKey="Mcgeer A">A. McGeer</name></author><author><name sortKey="Perl, T M" uniqKey="Perl T">T.M. Perl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arabi, Y M" uniqKey="Arabi Y">Y.M. Arabi</name></author><author><name sortKey="Alomari, A" uniqKey="Alomari A">A. Alomari</name></author><author><name sortKey="Mandourah, Y" uniqKey="Mandourah Y">Y. Mandourah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arabi, Y M" uniqKey="Arabi Y">Y.M. Arabi</name></author><author><name sortKey="Mandourah, Y" uniqKey="Mandourah Y">Y. Mandourah</name></author><author><name sortKey="Al Hameed, F" uniqKey="Al Hameed F">F. Al-Hameed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ahmed, A E" uniqKey="Ahmed A">A.E. Ahmed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Y M" uniqKey="Yang Y">Y.M. Yang</name></author><author><name sortKey="Hsu, C Y" uniqKey="Hsu C">C.Y. Hsu</name></author><author><name sortKey="Lai, C C" uniqKey="Lai C">C.C. Lai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Seys, L J" uniqKey="Seys L">L.J. Seys</name></author><author><name sortKey="Widagdo, W" uniqKey="Widagdo W">W. Widagdo</name></author><author><name sortKey="Verhamme, F M" uniqKey="Verhamme F">F.M. Verhamme</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author><author><name sortKey="Hui, D S" uniqKey="Hui D">D.S. Hui</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Who" uniqKey="Who">WHO</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="World Health Organization" uniqKey="World Health Organization">World Health Organization</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name></author><author><name sortKey="Muller, M A" uniqKey="Muller M">M.A. Muller</name></author><author><name sortKey="Costabel, U" uniqKey="Costabel U">U. Costabel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name></author><author><name sortKey="Albarrak, A M" uniqKey="Albarrak A">A.M. Albarrak</name></author><author><name sortKey="Omrani, A S" uniqKey="Omrani A">A.S. Omrani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hashem, A M" uniqKey="Hashem A">A.M. Hashem</name></author><author><name sortKey="Al Amri, S S" uniqKey="Al Amri S">S.S. Al-Amri</name></author><author><name sortKey="Al Subhi, T L" uniqKey="Al Subhi T">T.L. Al-Subhi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Who" uniqKey="Who">WHO</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author><author><name sortKey="Chan, J F" uniqKey="Chan J">J.F. Chan</name></author><author><name sortKey="Azhar, E I" uniqKey="Azhar E">E.I. Azhar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, J F" uniqKey="Chan J">J.F. Chan</name></author><author><name sortKey="Yao, Y" uniqKey="Yao Y">Y. Yao</name></author><author><name sortKey="Yeung, M L" uniqKey="Yeung M">M.L. Yeung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arabi, Y M" uniqKey="Arabi Y">Y.M. Arabi</name></author><author><name sortKey="Deeb, A M" uniqKey="Deeb A">A.M. Deeb</name></author><author><name sortKey="Al Hameed, F" uniqKey="Al Hameed F">F. Al-Hameed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arabi, Y M" uniqKey="Arabi Y">Y.M. Arabi</name></author><author><name sortKey="Alothman, A" uniqKey="Alothman A">A. Alothman</name></author><author><name sortKey="Balkhy, H H" uniqKey="Balkhy H">H.H. Balkhy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hui, D S" uniqKey="Hui D">D.S. Hui</name></author><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Kim, S W" uniqKey="Kim S">S.W. Kim</name></author><author><name sortKey="Park, J W" uniqKey="Park J">J.W. Park</name></author><author><name sortKey="Jung, H D" uniqKey="Jung H">H.D. Jung</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author><author><name sortKey="Zumla, A I" uniqKey="Zumla A">A.I. Zumla</name></author><author><name sortKey="Al Hakeem, R F" uniqKey="Al Hakeem R">R.F. Al-Hakeem</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Drosten, C" uniqKey="Drosten C">C. Drosten</name></author><author><name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name></author><author><name sortKey="Muller, M A" uniqKey="Muller M">M.A. Müller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oboho, I K" uniqKey="Oboho I">I.K. Oboho</name></author><author><name sortKey="Tomczyk, S M" uniqKey="Tomczyk S">S.M. Tomczyk</name></author><author><name sortKey="Al Asmari, A M" uniqKey="Al Asmari A">A.M. Al-Asmari</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Omrani, A S" uniqKey="Omrani A">A.S. Omrani</name></author><author><name sortKey="Matin, M A" uniqKey="Matin M">M.A. Matin</name></author><author><name sortKey="Haddad, Q" uniqKey="Haddad Q">Q. Haddad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Siegel, J D" uniqKey="Siegel J">J.D. Siegel</name></author><author><name sortKey="Rhinehart, E" uniqKey="Rhinehart E">E. Rhinehart</name></author><author><name sortKey="Jackson, M" uniqKey="Jackson M">M. Jackson</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Schindewolf, C" uniqKey="Schindewolf C">C. Schindewolf</name></author><author><name sortKey="Menachery, V D" uniqKey="Menachery V">V.D. Menachery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author><author><name sortKey="Alhakeem, R F" uniqKey="Alhakeem R">R.F. Alhakeem</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author><author><name sortKey="Mwaba, P" uniqKey="Mwaba P">P. Mwaba</name></author><author><name sortKey="Bates, M" uniqKey="Bates M">M. Bates</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author><author><name sortKey="Rustomjee, R" uniqKey="Rustomjee R">R. Rustomjee</name></author><author><name sortKey="Ntoumi, F" uniqKey="Ntoumi F">F. Ntoumi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hui, D S" uniqKey="Hui D">D.S. Hui</name></author><author><name sortKey="Perlman, S" uniqKey="Perlman S">S. Perlman</name></author><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author></analytic></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Clin North Am</journal-id><journal-id journal-id-type="iso-abbrev">Infect. Dis. Clin. North Am</journal-id><journal-title-group><journal-title>Infectious Disease Clinics of North America</journal-title></journal-title-group><issn pub-type="ppub">0891-5520</issn><issn pub-type="epub">1557-9824</issn><publisher><publisher-name>Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31668197</article-id><article-id pub-id-type="pmc">7127753</article-id><article-id pub-id-type="publisher-id">S0891-5520(19)30060-1</article-id><article-id pub-id-type="doi">10.1016/j.idc.2019.08.001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Middle East Respiratory Syndrome (MERS)</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Azhar</surname><given-names>Esam I.</given-names></name><degrees>PhD, FRCP</degrees><email>eazhar@kau.edu.sa</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">∗</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Hui</surname><given-names>David S.C.</given-names></name><degrees>MBBS, MD(UNSW), FRACP, FRCP(Lond, Edin, Glasg), FHKCP, FHKAM(Med)</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Memish</surname><given-names>Ziad A.</given-names></name><degrees>MD, FRCP</degrees><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Drosten</surname><given-names>Christian</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Zumla</surname><given-names>Alimuddin</given-names></name><degrees>MBChB, MSc, PhD, MD, FRCP(Lond), FRCP(Edin), FRCPath(UK), FAAS</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Special Infectious Agents Unit, King Fahd Medical Research Centre, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia</aff><aff id="aff2"><label>b</label>Department of Medicine and Therapeutics, Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong</aff><aff id="aff3"><label>c</label>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia</aff><aff id="aff4"><label>d</label>Infectious Diseases Division, Department of Medicine and Research, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia</aff><aff id="aff5"><label>e</label>Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany</aff><aff id="aff6"><label>f</label>Center for Clinical Microbiology, University College London, Royal Free Campus 2nd Floor, Rowland Hill Street, London NW3 2PF, United Kingdom</aff><author-notes><corresp id="cor1"><label>∗</label>Corresponding author. <email>eazhar@kau.edu.sa</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>25</day><month>10</month><year>2019</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>12</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>25</day><month>10</month><year>2019</year></pub-date><volume>33</volume><issue>4</issue><fpage>891</fpage><lpage>905</lpage><permissions><copyright-statement>© 2019 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="teaser" id="abs0010"><p>The Middle East respiratory syndrome (MERS) is a novel lethal zoonotic disease of humans caused by the MERS coronavirus (MERS-CoV). Although MERS is endemic to the Middle East, travelers have exported MERS-CoV on return to their home countries. Clinical manifestations range from mild to severe acute respiratory disease and death. The elderly, immunocompromised, and those with chronic comorbid liver, lung, and hepatic conditions have a high mortality rate. There is no specific treatment. Person-to-person spread causes hospital and household outbreaks, and thus improved compliance with internationally recommended infection control protocols and rapid implementation of infection control measures are required.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Middle East respiratory syndrome coronavirus</kwd><kwd>MERS-CoV</kwd><kwd>Epidemiology diagnosis</kwd><kwd>Treatment</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Key points</title><p id="p0010"><boxed-text id="dtbox1"><p id="p0015"><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>•</label><p id="p0020">The Middle East respiratory syndrome (MERS) is a novel lethal zoonotic disease of humans endemic to The Middle East, caused by the MERS coronavirus (MERS-CoV).</p></list-item><list-item id="u0015"><label>•</label><p id="p0025">Humans are thought to acquire MERS-CoV though contact with camels or camel products.</p></list-item><list-item id="u0020"><label>•</label><p id="p0030">MERS carries a 35% mortality rate. There is no specific treatment for MERS. Person-to-person spread causes hospital and household outbreaks of MERS-CoV.</p></list-item><list-item id="u0025"><label>•</label><p id="p0035">Millions of visitors travel to Saudi Arabia each year from across the world, thus watchful surveillance and a high degree of clinical awareness and early diagnosis with rapid implementation of infection control measures in returning travelers is important.</p></list-item></list></p></boxed-text></p></sec><sec id="sec2"><title>Introduction</title><p id="p0040">The Middle East respiratory syndrome coronavirus (MERS-CoV) is a new zoonotic human viral pathogen endemic to the Middle East.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> It was identified in 2012 in a lung sample of a 60-year-old patient who had died of respiratory failure in Jeddah, Saudi Arabia.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> The disease caused by MERS-CoV is named Middle East respiratory syndrome (MERS). MERS has remained on the radar of global public health authorities because of recurrent nosocomial and community outbreaks, and its association with severe disease and high mortality rates.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> Intermittent sporadic cases, community clusters, and nosocomial outbreaks of MERS-CoV have continued to occur in Saudi Arabia.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> MERS-CoV remains on the World Health Organization (WHO) Blueprint list of priority pathogens<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> because it remains a persistent threat to global health security.</p></sec><sec id="sec3"><title>Epidemic potential and global spread</title><p id="p0045">Cases of MERS from outside the Middle East have been reported from all continents, and have been linked with travel to the Middle East.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Nosocomial outbreaks of MERS-CoV infection accounts for approximately 40% of MERS-CoV cases globally. Large health care–associated outbreaks of MERS-CoV have occurred in Saudi Arabia, United Arab Emirates, and the Republic of Korea.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref> From June 1 to July 31, 2015, MERS-CoV caused the largest outbreak outside the Arabian Peninsula in the Republic of Korea, resulting in 186 confirmed MERS cases with 38 deaths.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> This occurred when a Korean traveler returning from a trip to Qatar, United Arab Emirates (UAE), Saudi Arabia, and Bahrain became ill with a respiratory illness and visited several hospitals before finally being diagnosed as having MERS-CoV infection on May 20, 2015, at Samsung Medical Center.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> This resulted in 186 people, including 25 health care workers (HCWs), contracting MERS-CoV infection; 181 of 186 cases were associated with hospital transmission. This outbreak clearly illustrated the epidemic potential of MERS-CoV, spreading person-to-person.</p></sec><sec id="sec4"><title>Epidemiology</title><p id="p0050">The number of MERS-CoV cases reported to the WHO have steadily increased since the first report of MERS-CoV in September 2012.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> MERS-CoV cases continue to be reported from the community and hospitals across the Arabian Peninsula. As of July 31st 2019, 2458 cases of laboratory-confirmed MERS cases were reported to WHO. Of these, there were 848 deaths (34% mortality)<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). Approximately 80% of human cases have been reported by Saudi Arabia. Twenty-seven countries have reported cases of MERS.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Countries in or near the Arabian Peninsula that report MERS cases are Bahrain, Iran, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, UAE, and Yemen. Cases identified outside the Middle East are usually in travelers who were infected in the Middle East and then traveled to areas outside the Middle East. Countries outside the Arabian Peninsula that have reported travel-associated MERS cases are Algeria, Austria, China, Egypt, France, Germany, Greece, Italy, Malaysia, Netherlands, Philippines, Republic of Korea, Thailand, Tunisia, Turkey, United Kingdom, and the United States.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><fig id="fig1"><label>Fig. 1</label><caption><p>Geographic distribution of MERS reported to WHO (2012–2018).</p></caption><graphic xlink:href="gr1_lrg"></graphic><attrib>(<italic>From</italic> WHO 2019.Middle East respiratory syndrome coronavirus (MERS-CoV. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/" id="intref0055">https://www.who.int/emergencies/mers-cov/en/</ext-link>; with permission.)</attrib></fig></p></sec><sec id="sec5"><title>Source of primary human Middle East respiratory syndrome coronavirus infections</title><p id="p0055">The exact mode of transmission of MERS-CoV to humans is not yet accurately defined. Epidemiologic, genetic, and phenotypic studies indicate that dromedary camels appear to be the main intermediary reservoirs of MERS-CoV.<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref> Camels are assumed to be intermediary host species for the MERS-CoV, although the exact source and the mode of transmission in many primary MERS cases remain unclear. Antibodies to MERS-CoV were detected in serum and milk collected from 33 camels in Qatar in April 2014. In one study, active virus shedding in nasal secretions and in feces was observed for 7 of 12 camels.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> MERS-CoV survives for prolonged periods in camel’s milk but viable virus became undetectable after pasteurization at 63°C for 30 minutes.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> MERS-CoV has been detected in camels from Kenya; 792 of 1163 camels studied had enzyme-linked immunosorbent assay (ELISA) seropositivity of which 11 camel nasal swabs were positive for MERS-CoV by quantitative reverse-transcription polymerase chain reaction (RT-PCR).<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> A study of humans in Kenya detected MERS-CoV neutralizing antibodies in persons living in rural areas, although no human MERS cases have been detected yet.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p><p id="p0060">The primary source of human MERS-CoV infections remains unknown. There are no definitive data on the epidemiologic link between human MERS-CoV infections and bats. Only one fragment of MERS-CoV with close matching to a human isolate of MERS-CoV was found in a study of more than 1000 samples from <italic>Taphozous</italic> bats.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Phylogenetic analysis of an MERS-related CoV identified from a <italic>Neoromicia capensis</italic> bat sampled in South Africa supports the hypothesis that bats are the evolutionary source of MERS-CoV but not a zoonotic reservoir.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> To date, no sustained human-to-human transmission has been documented, although tertiary and quaternary spread did occur in the Korean outbreak.<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref></p></sec><sec id="sec6"><title>Risk factors for primary Middle East respiratory syndrome coronavirus infection</title><p id="p0065">Several independent risk factors for increased susceptibility to acquiring primary MERS-CoV infections have been identified: direct dromedary exposure in the fortnight before illness onset, direct physical contact with dromedary camels during the previous 6 months, diabetes mellitus, and heart disease. Risk factors for MERS-CoV infection among camel workers include milking camels, contact with camel waste, poor hand hygiene before and after animal tasks and training activities, and workers with respiratory symptoms requiring overnight stay in hospital.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Viral RNA sequencing has confirmed camel to human transmission of MERS-CoV<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref> after known exposure to the infected camels. Recent data suggest that although MERS-CoV is widespread among dromedary camels in the Middle East and Africa, zoonotic transmission of MERS-CoV from camels to humans is relatively uncommon, and human disease is not directly proportional to potential exposure. MERS-CoV does not transmit easily from person-to-person unless there is close contact, such as occurs when providing care to a patient in the household<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> or nosocomial setting when the diagnosis of MERS-CoV has not yet been recognized and there are lapses in instituting infection control measures.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref></p></sec><sec id="sec7"><title>Clinical features</title><p id="p0070">The symptoms, signs, laboratory, and imaging abnormalities associated with MERS-CoV infection are not MERS-specific and are like other respiratory tract infections (RTIs)<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref> (<xref rid="tbox1" ref-type="boxed-text">Box 1</xref>, <xref rid="tbl1" ref-type="table">Table 1</xref>). The clinical manifestations of MERS-CoV infections range from asymptomatic infection to mild, moderate, and severe disease, often complicated by severe pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and multiorgan failure. The incubation period is between 2 and 14 days. Mild cases can have low-grade fever, chills, runny nose, dry cough, sore throat, and myalgia. Some patients have gastrointestinal symptoms, such as nausea, vomiting, and diarrhea. Fever may be absent in up to 15% of hospitalized cases. Laboratory abnormalities include cytopenias and elevated transaminases (see <xref rid="tbl1" ref-type="table">Table 1</xref>). Coinfections with other respiratory viruses and bacterial pathogens have been reported. Up to half of MERS cases can have acute kidney injury and one-third of very ill patients have gastrointestinal symptoms.<boxed-text id="tbox1"><label>Box 1</label><caption><title>Risk factors for nosocomial Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks</title></caption><p id="p0215"><list list-type="simple" id="ulist0020"><list-item id="u0045"><label>•</label><p id="p0220">Lack of awareness of the possibility of MERS in febrile patients presenting to</p></list-item><list-item id="u0050"><p id="p0225">health care facilities</p></list-item><list-item id="u0055"><label>•</label><p id="p0230">Overcrowded emergency departments where patients with MERS first present</p></list-item><list-item id="u0060"><label>•</label><p id="p0235">Exposure of health care workers and other patients to symptomatic MERS patients</p></list-item><list-item id="u0065"><label>•</label><p id="p0240">Poor compliance with infection control measures: (1) hand hygiene, (2) droplet and contact precautions, (3) inadequate environmental cleaning</p></list-item><list-item id="u0070"><label>•</label><p id="p0245">Inadequate compliance with appropriate Personal Protective Equipment</p></list-item><list-item id="u0075"><label>•</label><p id="p0250">Lack of proper isolation room facilities</p></list-item><list-item id="u0085"><label>•</label><p id="p0260">Aerosol-generating procedures on patients with MERS</p></list-item><list-item id="u0095"><label>•</label><p id="p0270">Crowded inpatient wards, including nonessential staff and visitors (family and friends)</p></list-item></list></p><attrib><italic>Data from</italic> Refs.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib51" ref-type="bibr">51</xref></attrib></boxed-text><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Clinical and laboratory features of patients with Middle East respiratory syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Clinical/Laboratory Feature(s)</th></tr></thead><tbody><tr><td>Date of first MERS case (place) (retrospective analyses)</td><td>April 2012 (Zarqa, Jordan)<break></break>June 2012 (Jeddah, Kingdom of Saudi Arabia)</td></tr><tr><td>Incubation period</td><td>Mean: 5.2 d (95% confidence interval 1.9–14.7)<break></break>Range: 2–14 d</td></tr><tr><td colspan="2">Age group</td></tr><tr><td> Adults</td><td>Adults (98%)</td></tr><tr><td> Children</td><td>Children (2%)</td></tr><tr><td>Age, y, range, median</td><td>Range:1–94; Median: 50</td></tr><tr><td>Gender</td><td>Male: 64.5%, Female: 35.5%</td></tr><tr><td>Presenting symptoms</td><td>Estimated proportion of cases, %</td></tr><tr><td>Fever >38°C</td><td>98</td></tr><tr><td>Chills/rigors</td><td>87</td></tr><tr><td><list list-type="simple" id="olist0010"><list-item id="u0030"><p id="p0200">Cough<list list-type="simple" id="ulist0015"><list-item id="u0035"><label>•</label><p id="p0205">Dry</p></list-item><list-item id="u0040"><label>•</label><p id="p0210">Productive</p></list-item></list></p></list-item></list></td><td>83<break></break>56<break></break>44</td></tr><tr><td>Shortness of breath</td><td>72</td></tr><tr><td>Myalgia</td><td>32</td></tr><tr><td>Malaise</td><td>38</td></tr><tr><td>Nausea</td><td>21</td></tr><tr><td>Vomiting</td><td>21</td></tr><tr><td>Diarrhea</td><td>26</td></tr><tr><td>Sore throat</td><td>14</td></tr><tr><td>Hemoptysis</td><td>17</td></tr><tr><td>Headache</td><td>11</td></tr><tr><td>Rhinorrhoea</td><td>6</td></tr><tr><td>Comorbidities (eg, obesity, diabetes, cardiac disease and lung disease), %</td><td>76</td></tr><tr><td>Laboratory results, %</td><td></td></tr><tr><td>Chest radiograph and computed tomography abnormalities</td><td>90–100</td></tr><tr><td>Leukopenia (<4.0 × 10<sup>9</sup>/L)</td><td>14</td></tr><tr><td>Lymphopenia (<1.5 × 10<sup>9</sup>/L)</td><td>32</td></tr><tr><td>Thrombocytopenia <140 × 10<sup>9</sup>/L)</td><td>36</td></tr><tr><td>Elevated lactate dehydrogenase</td><td>48</td></tr><tr><td>Elevated alanine transaminase</td><td>11</td></tr><tr><td>Elevated aspartate transaminase</td><td>14</td></tr><tr><td>Risk factors associated with poor outcome (severe disease or death)</td><td>Any immunocompromised state, comorbid illness, concomitant infections, low albumin, age ≥65 y</td></tr><tr><td colspan="2">Mortality, %</td></tr><tr><td> Case fatality rate (CFR), overall</td><td>34%</td></tr><tr><td> CFR in patients with comorbidities</td><td>60</td></tr></tbody></table><attrib><italic>Data from</italic> Refs.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib7" ref-type="bibr">7</xref></attrib></table-wrap></p><p id="p0075">Severe illness can cause respiratory failure that requires mechanical ventilation and support in an intensive care unit (ICU). There is rapid progression to ARDS and multisystem disease and organ failure with a median of 2 days from hospitalization to ICU admission.<xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref> MERS-CoV infection appears to cause more severe disease in older people, people with weakened immune systems, and those with chronic diseases, such as renal disease, cancer, chronic lung disease, and diabetes.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref></p></sec><sec id="sec8"><title>Mortality and risk factors</title><p id="p0080">A case study of 660 patients with MERS in Saudi Arabia seen between December 2, 2014, and November 12, 2016, found that 3-day, 30-day, and overall mortality were 13.8%, 28.3%, and 29.8%.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Patients older than 60 were more likely to die (45.2% mortality) from their infections than were younger patients (20%). Patients with preexisting medical comorbidities tend to have more severe disease and higher mortality rates.</p><p id="p0085">Factors associated with poor management outcomes (severe disease or death) in patients with MERS include old age, male gender, comorbid preexisting illnesses (such as obesity, diabetes mellitus, heart and lung disease, and immunocompromised states), low serum albumin, concomitant infections, and positive plasma MERS-CoV RNA.<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref> DPP4 receptors have been shown to be upregulated in the lungs of smokers, and this may explain why patients with comorbid lung diseases are prone to severe illness.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref></p></sec><sec id="sec9"><title>Making an early diagnosis of Middle East respiratory syndrome coronavirus infection</title><p id="p0090">Many cases of MERS-CoV can be easily missed because the presentation is that of any community-acquired pneumonia or other respiratory illness caused by influenza A and B respiratory syncytial virus, parainfluenza viruses, rhinoviruses, adenoviruses, enteroviruses (eg, EVD68), human metapneumovirus, and endemic human coronaviruses (ie, HCoV-HKU1, -OC43, -NL63, and -229E).<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Most nosocomial outbreaks of MERS-CoV have been associated with a delay in diagnosis.</p><p id="p0095">A history of travel to the Middle East is important for patients presenting in non-Middle Eastern countries with a febrile illness.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref></p></sec><sec id="sec10"><title>Risk factors for nosocomial Middle East respiratory syndrome coronavirus outbreaks</title><p id="p0100">Early and accurate diagnosis of MERS-CoV infection is important for clinical management, and instituting infection control and epidemiologic control measures of MERS-CoV infections. Thus, a high degree of clinical awareness of the possibility of MERS-CoV infection is required in all health care settings so that an accurate diagnosis can be made and infection control measures instituted as soon as the diagnosis is entertained clinically.<xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref></p></sec><sec id="sec11"><title>Clinical samples for laboratory testing</title><p id="p0105">Upper respiratory tract samples have yielded negative results in some symptomatic close contacts of confirmed cases who later developed pneumonia and tested positive on lower respiratory specimens. For laboratory testing, WHO<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> recommends that both upper respiratory tract specimens (nasopharyngeal and oropharyngeal) and lower respiratory tract specimens (sputum, tracheal aspirate, or lavage) are collected whenever possible. Lower respiratory specimens have a higher diagnostic value than upper respiratory tract specimens for detecting MERS-CoV infection.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> Sputum, endotracheal aspirate, or bronchoalveolar lavage should be collected for MERS-CoV testing when possible. If patients do not have signs or symptoms of lower respiratory tract disease and the collection of lower tract specimens is not possible or clinically indicated, upper respiratory tract specimens, such as a nasopharyngeal aspirate or combined nasopharyngeal and oropharyngeal swabs, should be collected.</p><p id="p0110">When taking nasopharyngeal and oropharyngeal specimens, Dacron or rayon swabs specifically designed for collecting specimens for virology must be used. These swab kits should contain virus transport medium. The nasopharyngeal and oropharyngeal swabs should be placed in the same tube to increase the viral load.<xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref> A single negative test result does not exclude the diagnosis, and repeat sampling and testing is strongly recommended. To confirm clearance of the virus, respiratory samples should be collected sequentially (every 2–4 days) over ensuing days until there are 2 consecutive negative results in clinically recovered persons. Specimens for MERS-CoV detection should reach the laboratory as soon as possible after collection and be delivered promptly to the laboratory, shipped at 4°C if possible. When there is likely to be a delay of more than 72 hours in specimens reaching the laboratory, it is recommended that the specimens are frozen at −20°C or ideally −80°C and shipped on dry ice. It is important to avoid repeated freezing and thawing of specimens.<xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref></p></sec><sec id="sec12"><title>Laboratory tests for Middle East respiratory syndrome coronavirus</title><p id="p0115">Accurate laboratory molecular diagnostic tests are available using highly sensitive and specific real-time RT-PCR (rRT-PCR). Three rRT-PCR assays for routine detection of MERS-CoV have been developed targeting upstream of the E protein gene (<italic>upE</italic>) and the open reading frame 1b (ORF 1b), and ORF 1a.<xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref> The assay for the upE target is considered highly sensitive and is recommended for screening, with the ORF 1a assay considered of equal sensitivity. To date, these rRT-PCR assays have shown no cross-reactivity with other respiratory viruses, including human coronaviruses, and were suitable to detect all known MERS-CoV strains in humans and dromedary camels.</p><p id="p0120">Laboratory confirmation of MERS-CoV infection<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> is obtained by detection of the virus by (1) MERS-CoV–specific nucleic acid amplification test with up to 2 separate targets and/or sequencing; (2) virus isolation in tissue culture; or (3) serology on serum tested in a WHO collaborating center with established testing methods.<xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref> A case confirmed by serology requires demonstration of seroconversion in 2 samples ideally taken at least 14 days apart, by a screening (ELISA, immunofluorescence assay) and a neutralization assay.</p><p id="p0125">Serologic tests such as ELISAs for MERS-CoV are being developed and refined for surveillance or investigational purposes.<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib38" ref-type="bibr">38</xref> An indirect ELISA has been developed for sero-epidemiological testing and surveillance purposes and requires evaluation in field studies.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref></p><p id="p0130">MERS-CoV testing must be performed in appropriately equipped biosafety laboratories by staff trained in the relevant technical and safety procedures. National or WHO guidelines on laboratory biosafety should be followed in all circumstances.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref></p></sec><sec id="sec13"><title>Clinical management of Middle East respiratory syndrome cases</title><p id="p0135">The management of patients with MERS is largely symptomatic and supportive and aims to reduce the risk of complications, such as secondary infections, and renal and respiratory failure.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> Seriously ill patients should receive intensive care.</p><p id="p0140">Although a range of existing and developmental treatments may be useful<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> (<xref rid="tbox2" ref-type="boxed-text">Box 2</xref>), currently there are no specific treatments to treat MERS-CoV. A range of treatments such as lopinavir/ritonavir, pegylated interferon (IFN)-α2a, and ribavirin have been used empirically for serious cases of MERS but there is no accurate evidence base that any of them improve treatment outcomes. Treatment with either lopinavir/ritonavir or IFN-β1b in the marmoset model was associated with improved clinical, radiological, and pathologic outcomes with lower viral loads in comparison with no treatment, whereas mycophenolic acid alone increased viral loads and fatality.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Macrolide therapy is commonly started before the patient arrives in the ICU in Saudi Arabia. A retrospective study of 136 patients with MERS found that macrolide therapy is not associated with a reduction in mortality or improvement in MERS-CoV RNA clearance.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><boxed-text id="tbox2"><label>Box 2</label><caption><title>Potential treatments for MERS-CoV infection</title></caption><p id="p0275"><list list-type="simple" id="ulist0025"><list-item id="u0100"><label>•</label><p id="p0280">Antivirals<list list-type="simple" id="ulist0030"><list-item id="u0105"><label>○</label><p id="p0285">Ribavirin monotherapy<sup>a</sup> (± interferon)</p></list-item><list-item id="u0110"><label>○</label><p id="p0290">Human immunodeficiency virus protease inhibitors (lopinavir,<sup>b</sup> nelfinavir)</p></list-item></list></p></list-item><list-item id="u0115"><label>•</label><p id="p0295">Repurposed drugs:<list list-type="simple" id="ulist0035"><list-item id="u0120"><label>○</label><p id="p0300">Cyclophilin inhibitors (ciclosporin, alisporivir)</p></list-item><list-item id="u0125"><label>○</label><p id="p0305">Chloroquine (active in vitro)</p></list-item><list-item id="u0130"><label>○</label><p id="p0310">Mycophenolic acid</p></list-item><list-item id="u0135"><label>○</label><p id="p0315">Nitazoxanide</p></list-item></list></p></list-item><list-item id="u0140"><label>•</label><p id="p0320">Interferons<sup>b</sup>:<list list-type="simple" id="ulist0040"><list-item id="u0145"><label>○</label><p id="p0325">Interferon alfa</p></list-item><list-item id="u0150"><label>○</label><p id="p0330">Interferon beta</p></list-item></list></p></list-item><list-item id="u0155"><label>•</label><p id="p0335">Neutralizing antibodies<sup>b</sup>:<list list-type="simple" id="ulist0045"><list-item id="u0160"><label>○</label><p id="p0340">Convalescent plasma</p></list-item><list-item id="u0165"><label>○</label><p id="p0345">Polyclonal human immunoglobulin from transgenic cows</p></list-item><list-item id="u0170"><label>○</label><p id="p0350">Equine F(ab’)2 antibody fragments</p></list-item><list-item id="u0175"><label>○</label><p id="p0355">Camel antibodies</p></list-item><list-item id="u0180"><label>○</label><p id="p0360">Anti-S monoclonal antibodies</p></list-item></list></p></list-item><list-item id="u0185"><label>•</label><p id="p0365">Recombinant human mannose-binding lectin</p></list-item><list-item id="u0190"><label>•</label><p id="p0370">Small interfering RNA to key MERS-CoV genes</p></list-item></list></p><p id="p0375"><sup>a</sup> Risks likely to exceed benefits.</p><p id="p0380"><sup>b</sup> Treatment benefits likely to exceed risks.</p><attrib><italic>Adapted from</italic> Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386(9997):995-1007; and Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.</attrib></boxed-text></p><p id="p0145">Currently there is an ongoing randomized controlled trial in progress in the Kingdom of Saudi Arabia comparing lopinavir/ritonavir, recombinant IFN-β1b, and standard supportive care against placebo and standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> Systemic corticosteroids were shown to delay viral clearance in critically ill patients with MERS-CoV infection.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> A range of anti–MERS-CoV drugs and host-directed therapies are being considered as potential therapies for MERS-CoV.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> Properly designed studies are needed to answer several knowledge gaps for us to understand the disease pathogenesis, viral kinetics, mode of disease transmission, and the intermediary source of MERS to guide infection control prevention measures and treatment responses in MERS-CoV infection.</p></sec><sec id="sec14"><title>Infection control measures in hospitals when Middle East respiratory syndrome coronavirus infection is suspected</title><p id="p0150">The main infection prevention and control measures for managing patients with MERS are well documented from the severe acute respiratory syndrome (SARS) epidemic.<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> Early identification and isolation of suspected or confirmed cases and ongoing surveillance are key to preventing nosocomial spread. Droplet precaution (wearing a surgical mask within 1 m of the patient) and contact and droplet precautions (wearing gown, gloves, mask, and eye protection on entering the room and removing them on leaving) must be used when caring for patients with suspected MERS-CoV infection.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> HCWs should implement airborne precautions and wear a fit-tested particulate respirator (eg, The US National Institute for Occupational Safety and Health–approved N95 filtering facepiece respirator [FFR] or an European norms [EN] approved FFP2-FFR or FFP3-FFR) when performing aerosol-generating procedures for infected and potentially infected patients. Avoiding aerosolizing procedures in crowded hospital emergency or inpatient medical wards that do not have adequate infection control measures in place may decrease MERS-CoV human-to-human spread and environmental contamination. It is also prudent to use higher levels of protection for HCWs who extend close contact with patients with MERS and those who are exposed to aerosols from high-risk procedures.</p><p id="p0155">Higher levels of ventilation (more air changes, higher air flow and velocity), greater effort to prevent air dispersion beyond the point of generation (enclosure, using capture ventilation), and higher levels of personal protective equipment (more coverage, more protective types of respiratory protection) are all necessary. To reduce room contamination in the hospital setting, the application of a minimum room ventilation rate of 12 air changes per hour in a single room or at least 160 L/s per patient in facilities with natural ventilation is recommended when caring for patients receiving mechanical ventilation and during aerosol-generating procedures.</p></sec><sec id="sec15"><title>Decreasing risk of transmission</title><p id="p0160">Instituting appropriate infection control measures as soon as the diagnosis is considered is critical to preventing spread, especially in hospitals. Because symptoms and signs of RTIs are nonspecific, it is difficult to diagnose primary cases of patients with MERS-CoV infection. Infection prevention and control measures are important to prevent the spread of MERS-CoV within households, the community, and in health care facilities.</p></sec><sec id="sec16"><title>Transmission in hospitals</title><p id="p0165">Human-to-human transmission occurs within communities, households, and, more strikingly, within hospital settings. Health care–associated outbreaks have occurred in several countries, with the largest outbreaks seen in Saudi Arabia, UAE, and the Republic of Korea. Several outbreak studies have shown that MERS-CoV does not appear to transmit easily from person-to-person unless there is close contact, such as providing clinical care.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref> MERS-CoV has been identified in clinical specimens, such as sputum, endotracheal aspirate, bronchoalveolar lavage, nasal or nasopharyngeal swabs, urine, feces, blood, and lung tissue.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> The modes of MERS-CoV transmission through direct or indirect contact, airborne, droplet, or ingestion have yet to be defined.</p><p id="p0170">The upsurge in the number of human infections due to MERS-CoV over the past few years in health care facilities in the Middle East and South Korea<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref> were related to low awareness for MERS-CoV infection resulting in nosocomial outbreaks involving existing hospitalized patients, outpatients, visitors, and HCWs within health care facilities with overcrowding, lack of isolation room facilities, environmental contamination, and inadequate infection control measures without any significant change in the transmissibility of the virus. HCWs should always undertake standard precautions consistently with all patients with fever and symptoms of RTIs. Droplet precautions should be added to the standard precautions when providing care to these patients, and contact precautions and eye protection should be included when caring for probable or confirmed cases of MERS-CoV. Airborne precautions are important when performing aerosol-generating procedures.</p></sec><sec id="sec17"><title>Household transmission</title><p id="p0175">Human-to-human transmission in the community or in those living in large households and family compounds has been described.<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref> An investigation of 280 household contacts of 26 index MERS-CoV–infected Saudi Arabian patients, with follow-up serologic analysis in 44 contacts performed in 2014 to determine the rate of “silent or subclinical” secondary infection after exposure to primary cases of MERS-CoV infection, found there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2–7).<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> There have been several reports of MERS-CoV carriage after exposure to patients with MERS. Apparently healthy household contacts have been found to have MERS-CoV in their upper respiratory tract. Low levels of MERS-CoV RNA have been detected in asymptomatic HCWs from nosocomial MERS-CoV outbreaks in a Jeddah hospital.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> Of 79 relatives who were investigated after MERS-CoV infections affected an extended family in Saudi Arabia in 2014, 19 (24%) were MERS-CoV positive; 11 were hospitalized, and 2 died.</p></sec><sec id="sec18"><title>Health care worker and community education</title><p id="p0180">In MERS-CoV endemic countries where MERS-CoV cases can occur in the community and households, educational awareness of MERS-CoV and MERS prevention measures may reduce the risk of household transmission and prevent community clusters.<xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref> Regular hand washing before and after touching camels and avoiding contact with sick camels is advised. People should avoid drinking raw camel milk or camel urine or eating camel meat that has not been properly cooked. Persons who have diabetes, kidney disease, chronic lung disease, or cancer or are on immunosuppressive treatment are at high risk of developing severe MERS-CoV disease, thus they should avoid close contact with camels and bats.</p><p id="p0185">WHO does not advise special screening for MERS-CoV at points of entry after return from the Middle East nor does it currently recommend the application of any travel or trade restrictions.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Persons with a history of travel from or to the Arabian Peninsula within 10 days of developing symptoms of an acute respiratory infection involving fever of 38°C or more, or cough with radiologic pulmonary changes at presentation should alert the physician to the possibility of MERS-CoV infection.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref></p></sec><sec id="sec19"><title>Middle East respiratory syndrome coronavirus vaccines</title><p id="p0190">No vaccines are yet available that can protect against MERS-CoV infection. There are several groups working on developing a vaccine using a variety of platforms and some have shown efficacy in animal models.<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref></p></sec><sec id="sec20"><title>Summary</title><p id="p0195">MERS-CoV remains an important public health risk and possible consequences of further international spread could be serious in view of the patterns of nosocomial transmission within health care facilities. With 10 million pilgrims visiting Saudi Arabia each year from 182 countries to perform the Hajj and Umrah pilgrimages,<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> watchful surveillance by public health systems and a high degree of clinical awareness of the possibility of MERS-CoV infection is essential.<xref rid="bib58" ref-type="bibr">58</xref>, <xref rid="bib59" ref-type="bibr">59</xref>, <xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref> Nosocomial transmission is often due to a delayed diagnosis of MERS-CoV infection in a patient shedding MERS-CoV in a crowded health care setting such as an inpatient ward, emergency department, or renal dialysis unit. Early recognition of cases, improved compliance with internationally recommended infection control protocols, and rapid implementation of infection control measures are required to prevent health care facility–associated outbreaks of MERS-CoV.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="other" id="sref1"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV)</article-title><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/" id="intref0010">https://www.who.int/emergencies/mers-cov/en/</ext-link><year>2019</year><comment>Accessed June 1, 2019</comment></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Middle East respiratory syndrome</article-title><source>Lancet</source><volume>386</volume><issue>9997</issue><year>2015</year><fpage>995</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">26049252</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Balkhy</surname><given-names>H.H.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name></person-group><article-title>Middle East Respiratory syndrome</article-title><source>N Engl J Med</source><volume>376</volume><issue>6</issue><year>2017</year><fpage>584</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">28177862</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N Engl J Med</source><volume>367</volume><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="other" id="sref5"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><article-title>List of priority Blueprint diseases</article-title><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/en/" id="intref0015">https://www.who.int/blueprint/priority-diseases/en/</ext-link><comment>Accessed January 20, 2019</comment></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Alanazi</surname><given-names>K.H.</given-names></name><name><surname>Killerby</surname><given-names>M.E.</given-names></name><name><surname>Biggs</surname><given-names>H.M.</given-names></name></person-group><article-title>Scope and extent of healthcare-associated Middle East respiratory syndrome coronavirus transmission during two contemporaneous outbreaks in Riyadh, Saudi Arabia, 2017</article-title><source>Infect Control Hosp Epidemiol</source><volume>40</volume><issue>1</issue><year>2019</year><fpage>79</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">30595141</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>M.D.</given-names></name><name><surname>Choe</surname><given-names>P.G.</given-names></name><name><surname>Oh</surname><given-names>H.S.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus superspreading event involving 81 persons, Korea 2015</article-title><source>J Korean Med Sci</source><volume>30</volume><issue>11</issue><year>2015</year><fpage>1701</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">26539018</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>M.D.</given-names></name><name><surname>Park</surname><given-names>W.B.</given-names></name><name><surname>Choe</surname><given-names>P.G.</given-names></name></person-group><article-title>Viral load kinetics of MERS coronavirus infection</article-title><source>N Engl J Med</source><volume>375</volume><issue>13</issue><year>2016</year><fpage>1303</fpage><lpage>1305</lpage></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>C.K.</given-names></name><name><surname>Song</surname><given-names>K.H.</given-names></name><name><surname>Choe</surname><given-names>P.G.</given-names></name></person-group><article-title>Clinical and epidemiologic characteristics of spreaders of Middle East respiratory syndrome coronavirus during the 2015 outbreak in Korea</article-title><source>J Korean Med Sci</source><volume>32</volume><issue>5</issue><year>2017</year><fpage>744</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">28378546</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Kim</surname><given-names>Y.J.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission</article-title><source>Lancet Infect Dis</source><volume>18</volume><issue>8</issue><year>2018</year><fpage>e217</fpage><lpage>e227</lpage><pub-id pub-id-type="pmid">29680581</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="other" id="sref11"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><article-title>MERS Global summary and assessment of risk</article-title><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/coronavirus_infections/risk-assessment-august-2018.pdf" id="intref0020">https://www.who.int/csr/disease/coronavirus_infections/risk-assessment-august-2018.pdf</ext-link><comment>Accessed January 21, 2019</comment></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Reusken</surname><given-names>C.B.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Müller</surname><given-names>M.A.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study</article-title><source>Lancet Infect Dis</source><volume>13</volume><issue>10</issue><year>2013</year><fpage>859</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">23933067</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Reusken</surname><given-names>C.B.</given-names></name><name><surname>Farag</surname><given-names>E.A.</given-names></name><name><surname>Jonges</surname><given-names>M.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, 2014</article-title><source>Euro Surveill</source><volume>19</volume><issue>23</issue><year>2014</year><comment>[pii:20829]</comment></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Kellam</surname><given-names>P.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Evidence for camel-to-human transmission of MERS coronavirus</article-title><source>N Engl J Med</source><volume>371</volume><issue>14</issue><year>2014</year><fpage>1359</fpage><lpage>1360</lpage><pub-id pub-id-type="pmid">25271615</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Conzade</surname><given-names>R.</given-names></name><name><surname>Grant</surname><given-names>R.</given-names></name><name><surname>Malik</surname><given-names>M.R.</given-names></name></person-group><article-title>Reported direct and indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases</article-title><source>Viruses</source><volume>10</volume><issue>8</issue><year>2018</year><comment>[pii:E425]</comment></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Bushmaker</surname><given-names>T.</given-names></name><name><surname>Munster</surname><given-names>V.J.</given-names></name></person-group><article-title>Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions</article-title><source>Euro Surveill</source><volume>18</volume><issue>38</issue><year>2013</year><comment>[pii:20590]</comment></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Ommeh</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zohaib</surname><given-names>A.</given-names></name></person-group><article-title>Genetic evidence of Middle East respiratory syndrome coronavirus (MERS-Cov) and widespread seroprevalence among camels in Kenya</article-title><source>Virol Sin</source><year>2018</year></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Liljander</surname><given-names>A.</given-names></name><name><surname>Meyer</surname><given-names>B.</given-names></name><name><surname>Jores</surname><given-names>J.</given-names></name></person-group><article-title>MERS-CoV Antibodies in Humans, Africa, 2013-2014</article-title><source>Emerg Infect Dis</source><volume>22</volume><issue>6</issue><year>2016</year><fpage>1086</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">27071076</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Mishra</surname><given-names>N.</given-names></name><name><surname>Olival</surname><given-names>K.J.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus in bats, Saudi Arabia</article-title><source>Emerg Infect Dis</source><volume>19</volume><issue>11</issue><year>2013</year><fpage>1819</fpage><lpage>1823</lpage><pub-id pub-id-type="pmid">24206838</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Ithete</surname><given-names>N.L.</given-names></name><name><surname>Richards</surname><given-names>L.R.</given-names></name></person-group><article-title>Rooting the phylogenetic tree of Middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat</article-title><source>J Virol</source><volume>88</volume><year>2014</year><fpage>11297</fpage><lpage>11303</lpage><pub-id pub-id-type="pmid">25031349</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Sikkema</surname><given-names>R.S.</given-names></name><name><surname>Farag</surname><given-names>E.A.</given-names></name><name><surname>Himatt</surname><given-names>S.</given-names></name></person-group><article-title>Risk factors for primary Middle East respiratory syndrome coronavirus infection in camel workers in Qatar during 2013-2014: a case-control study</article-title><source>J Infect Dis</source><volume>215</volume><issue>11</issue><year>2017</year><fpage>1702</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">28387845</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>El-Kafrawy</surname><given-names>S.A.</given-names></name><name><surname>Farraj</surname><given-names>S.A.</given-names></name></person-group><article-title>Evidence for camel-to-human transmission of MERS coronavirus</article-title><source>N Engl J Med</source><volume>370</volume><issue>26</issue><year>2014</year><fpage>2499</fpage><lpage>2505</lpage><pub-id pub-id-type="pmid">24896817</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Cotten</surname><given-names>M.</given-names></name><name><surname>Meyer</surname><given-names>B.</given-names></name></person-group><article-title>Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013</article-title><source>Emerg Infect Dis</source><volume>20</volume><issue>6</issue><year>2014</year><fpage>1012</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">24857749</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Al Hammadi</surname><given-names>Z.M.</given-names></name><name><surname>Chu</surname><given-names>D.K.</given-names></name><name><surname>Eltahir</surname><given-names>Y.M.</given-names></name></person-group><article-title>Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015</article-title><source>Emerg Infect Dis</source><volume>21</volume><issue>12</issue><year>2015</year><fpage>2197</fpage><lpage>2200</lpage><pub-id pub-id-type="pmid">26584223</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Arwady</surname><given-names>M.A.</given-names></name><name><surname>Alraddadi</surname><given-names>B.</given-names></name><name><surname>Basler</surname><given-names>C.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus transmission in extended family, Saudi Arabia, 2014</article-title><source>Emerg Infect Dis</source><volume>22</volume><issue>8</issue><year>2016</year><fpage>1395</fpage><lpage>1402</lpage><pub-id pub-id-type="pmid">27191038</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Al-Abdallat</surname><given-names>M.M.</given-names></name><name><surname>Payne</surname><given-names>D.C.</given-names></name><name><surname>Alqasrawi</surname><given-names>S.</given-names></name><collab>Jordan MERS-CoV Investigation Team</collab></person-group><article-title>Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description</article-title><source>Clin Infect Dis</source><volume>59</volume><issue>9</issue><year>2014</year><fpage>1225</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">24829216</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Garbati</surname><given-names>M.A.</given-names></name><name><surname>Fagbo</surname><given-names>S.F.</given-names></name><name><surname>Fang</surname><given-names>V.J.</given-names></name></person-group><article-title>Comparative study of clinical presentation and risk factors for adverse outcome in patients hospitalised with acute respiratory disease due to MERS coronavirus or other causes</article-title><source>PLoS One</source><volume>11</volume><issue>11</issue><year>2016</year><fpage>e0165978</fpage><pub-id pub-id-type="pmid">27812197</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Assiri</surname><given-names>A.</given-names></name><name><surname>McGeer</surname><given-names>A.</given-names></name><name><surname>Perl</surname><given-names>T.M.</given-names></name><collab>KSA MERS-CoV Investigation Team</collab></person-group><article-title>Hospital outbreak of Middle East respiratory syndrome coronavirus</article-title><source>N Engl J Med</source><volume>369</volume><issue>5</issue><year>2013</year><fpage>407</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">23782161</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Alomari</surname><given-names>A.</given-names></name><name><surname>Mandourah</surname><given-names>Y.</given-names></name></person-group><article-title>Critically ill healthcare workers with the Middle East Respiratory Syndrome (MERS)</article-title><source>Crit Care Med</source><volume>45</volume><issue>10</issue><year>2017</year><fpage>1683</fpage><lpage>1695</lpage><pub-id pub-id-type="pmid">28787295</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Mandourah</surname><given-names>Y.</given-names></name><name><surname>Al-Hameed</surname><given-names>F.</given-names></name></person-group><article-title>Corticosteroid therapy for critically ill patients with middle east respiratory syndrome</article-title><source>Am J Respir Crit Care Med</source><volume>197</volume><issue>6</issue><year>2018</year><fpage>757</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">29161116</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>A.E.</given-names></name></person-group><article-title>The predictors of 3- and 30-day mortality in 660 MERS-CoV patients</article-title><source>BMC Infect Dis</source><volume>17</volume><issue>1</issue><year>2017</year><fpage>615</fpage><pub-id pub-id-type="pmid">28893197</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.M.</given-names></name><name><surname>Hsu</surname><given-names>C.Y.</given-names></name><name><surname>Lai</surname><given-names>C.C.</given-names></name></person-group><article-title>Impact of comorbidity on fatality rate of patients with middle east respiratory syndrome</article-title><source>Sci Rep</source><volume>7</volume><issue>1</issue><year>2017</year><fpage>11307</fpage><pub-id pub-id-type="pmid">28900101</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Seys</surname><given-names>L.J.</given-names></name><name><surname>Widagdo</surname><given-names>W.</given-names></name><name><surname>Verhamme</surname><given-names>F.M.</given-names></name></person-group><article-title>DPP4, the MERS coronavirus receptor, is upregulated in lungs of smokers and COPD patients</article-title><source>Clin Infect Dis</source><volume>66</volume><issue>1</issue><year>2018</year><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">29020176</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name></person-group><article-title>Infection control and MERS-CoV in health-care workers</article-title><source>Lancet</source><volume>383</volume><issue>9932</issue><year>2014</year><fpage>1869</fpage><lpage>1871</lpage><pub-id pub-id-type="pmid">24857701</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="other" id="sref35"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><article-title>Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected. Interim guidance January 2019</article-title><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/178529/WHO_MERS_Clinical_15.1_eng.pdf;jsessionid=C30F5404588BE9AA533F2B350A0FED4C?sequence=1" id="intref0025">https://apps.who.int/iris/bitstream/handle/10665/178529/WHO_MERS_Clinical_15.1_eng.pdf;jsessionid=C30F5404588BE9AA533F2B350A0FED4C?sequence=1</ext-link><comment>Accessed June 1, 2019</comment></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="book" id="sref36"><person-group person-group-type="author"><name><surname>World Health Organization</surname></name></person-group><chapter-title>Laboratory testing for Middle East respiratory syndrome coronavirus. Interim guidance revised January 2018</chapter-title><year>2018</year><publisher-name>WHO</publisher-name><publisher-loc>Geneva (Switzerland)</publisher-loc><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/259952/WHO-MERS-LAB-15.1-Rev1-2018-eng.pdf?sequence=1" id="intref0030">https://apps.who.int/iris/bitstream/handle/10665/259952/WHO-MERS-LAB-15.1-Rev1-2018-eng.pdf?sequence=1</ext-link><comment>Accessed June 1, 2019</comment></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Muller</surname><given-names>M.A.</given-names></name><name><surname>Costabel</surname><given-names>U.</given-names></name></person-group><article-title>Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections</article-title><source>Euro Surveill</source><volume>17</volume><year>2012</year><fpage>20334</fpage><pub-id pub-id-type="pmid">23231891</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Albarrak</surname><given-names>A.M.</given-names></name><name><surname>Omrani</surname><given-names>A.S.</given-names></name></person-group><article-title>Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection</article-title><source>Clin Infect Dis</source><volume>62</volume><issue>4</issue><year>2016</year><fpage>477</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">26565003</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Hashem</surname><given-names>A.M.</given-names></name><name><surname>Al-Amri</surname><given-names>S.S.</given-names></name><name><surname>Al-Subhi</surname><given-names>T.L.</given-names></name></person-group><article-title>Development and validation of different indirect ELISAs for MERS-CoV serological testing</article-title><source>J Immunol Methods</source><volume>466</volume><year>2019</year><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">30659836</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="other" id="sref40"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><article-title>Laboratory biorisk management for laboratories handling human specimens suspected of confirmed to contain novel coronavirus: interim recommendations</article-title><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/disease/coronavirus_infections/Biosafety_InterimRecommendations_NovelCoronavirus_19Feb13.pdf?ua=1" id="intref0035">https://www.who.int/csr/disease/coronavirus_infections/Biosafety_InterimRecommendations_NovelCoronavirus_19Feb13.pdf?ua=1</ext-link><comment>Accessed March 22, 2019</comment></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name></person-group><article-title>Coronaviruses - drug discovery and therapeutic options</article-title><source>Nat Rev Drug Discov</source><volume>15</volume><issue>5</issue><year>2016</year><fpage>327</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">26868298</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Yeung</surname><given-names>M.L.</given-names></name></person-group><article-title>Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset</article-title><source>J Infect Dis</source><volume>212</volume><issue>12</issue><year>2015</year><fpage>1904</fpage><lpage>1913</lpage><pub-id pub-id-type="pmid">26198719</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Deeb</surname><given-names>A.M.</given-names></name><name><surname>Al-Hameed</surname><given-names>F.</given-names></name></person-group><article-title>Macrolides in critically ill patients with Middle East Respiratory syndrome</article-title><source>Int J Infect Dis</source><volume>81</volume><year>2019</year><fpage>184</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">30690213</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Alothman</surname><given-names>A.</given-names></name><name><surname>Balkhy</surname><given-names>H.H.</given-names></name></person-group><article-title>Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial</article-title><source>Trials</source><volume>19</volume><issue>1</issue><year>2018</year><fpage>81</fpage><pub-id pub-id-type="pmid">29382391</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Severe acute respiratory syndrome vs. the Middle East respiratory syndrome</article-title><source>Curr Opin Pulm Med</source><volume>20</volume><issue>3</issue><year>2014</year><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">24626235</pub-id></element-citation></ref><ref id="bib46"><label>46</label><mixed-citation publication-type="other" id="sref46">WHO. Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection -Interim guidance. Available at: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/174652/WHO_MERS_IPC_15.1_eng.pdf;jsessionid=F6766551B38E85D0DE2FBBDEB17A0892?sequence=1" id="interref0010">https://apps.who.int/iris/bitstream/handle/10665/174652/WHO_MERS_IPC_15.1_eng.pdf;jsessionid=F6766551B38E85D0DE2FBBDEB17A0892?sequence=1</ext-link>. Accessed September 14, 2019.</mixed-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.W.</given-names></name><name><surname>Park</surname><given-names>J.W.</given-names></name><name><surname>Jung</surname><given-names>H.D.</given-names></name></person-group><article-title>Risk factors for transmission of Middle East respiratory syndrome coronavirus infection during the 2015 outbreak in South Korea</article-title><source>Clin Infect Dis</source><volume>64</volume><issue>5</issue><year>2017</year><fpage>551</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">27940937</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><collab>Korea Centers for Disease Control and Prevention</collab></person-group><article-title>Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015</article-title><source>Osong Public Health Res Perspect</source><volume>6</volume><year>2015</year><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">26473095</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Zumla</surname><given-names>A.I.</given-names></name><name><surname>Al-Hakeem</surname><given-names>R.F.</given-names></name></person-group><article-title>Family cluster of Middle East respiratory syndrome coronavirus infections</article-title><source>N Engl J Med</source><volume>368</volume><issue>26</issue><year>2013</year><fpage>2487</fpage><lpage>2494</lpage><pub-id pub-id-type="pmid">23718156</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Meyer</surname><given-names>B.</given-names></name><name><surname>Müller</surname><given-names>M.A.</given-names></name></person-group><article-title>Transmission of MERS-coronavirus in household contacts</article-title><source>N Engl J Med</source><volume>371</volume><issue>9</issue><year>2014</year><fpage>828</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">25162889</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Oboho</surname><given-names>I.K.</given-names></name><name><surname>Tomczyk</surname><given-names>S.M.</given-names></name><name><surname>Al-Asmari</surname><given-names>A.M.</given-names></name></person-group><article-title>2014 MERS-CoV outbreak in Jeddah–a link to health care facilities</article-title><source>N Engl J Med</source><volume>372</volume><issue>9</issue><year>2015</year><fpage>846</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">25714162</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Omrani</surname><given-names>A.S.</given-names></name><name><surname>Matin</surname><given-names>M.A.</given-names></name><name><surname>Haddad</surname><given-names>Q.</given-names></name></person-group><article-title>A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case</article-title><source>Int J Infect Dis</source><volume>17</volume><issue>9</issue><year>2013</year><fpage>e668</fpage><lpage>e672</lpage><pub-id pub-id-type="pmid">23916548</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>J.D.</given-names></name><name><surname>Rhinehart</surname><given-names>E.</given-names></name><name><surname>Jackson</surname><given-names>M.</given-names></name></person-group><article-title>Health care infection control practices advisory committee</article-title><source>Am J Infect Control</source><volume>35</volume><issue>10 Suppl 2</issue><year>2007</year><fpage>S65</fpage><lpage>S164</lpage><pub-id pub-id-type="pmid">18068815</pub-id></element-citation></ref><ref id="bib54"><label>54</label><mixed-citation publication-type="other" id="sref54">MERS-CoV daily update. Saudi Arabia: Ministry of Health. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.moh.gov.sa/en/CCC/PressReleases/" id="intref0040">https://www.moh.gov.sa/en/CCC/PressReleases/</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html" id="intref0045">http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html</ext-link>. Accessed July 31, 2019.</mixed-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="other" id="sref55"><person-group person-group-type="author"><collab>ISARIC and Public Health England</collab></person-group><article-title>Treatment of MERS-CoV: Information for Clinicians. Clinical decision-making support for treatment of MERS-CoV patient</article-title><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/360424/MERS_COV_information_for_clinicians_17_July.pdf" id="intref0050">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/360424/MERS_COV_information_for_clinicians_17_July.pdf</ext-link><comment>Accessed June 21, 2019</comment></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Schindewolf</surname><given-names>C.</given-names></name><name><surname>Menachery</surname><given-names>V.D.</given-names></name></person-group><article-title>Middle East respiratory syndrome vaccine candidates: cautious optimism</article-title><source>Viruses</source><issue>1</issue><year>2019</year><fpage>11</fpage><comment>[pii:E74]</comment></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Alhakeem</surname><given-names>R.F.</given-names></name></person-group><article-title>Hajj: infectious disease surveillance and control</article-title><source>Lancet</source><volume>383</volume><issue>9934</issue><year>2014</year><fpage>2073</fpage><lpage>2082</lpage><pub-id pub-id-type="pmid">24857703</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Mwaba</surname><given-names>P.</given-names></name><name><surname>Bates</surname><given-names>M.</given-names></name></person-group><article-title>The Hajj pilgrimage and surveillance for Middle East Respiratory syndrome coronavirus in pilgrims from African countries</article-title><source>Trop Med Int Health</source><volume>19</volume><issue>7</issue><year>2014</year><fpage>838</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">24750482</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Rustomjee</surname><given-names>R.</given-names></name><name><surname>Ntoumi</surname><given-names>F.</given-names></name></person-group><article-title>Middle East Respiratory Syndrome–need for increased vigilance and watchful surveillance for MERS-CoV in sub-Saharan Africa</article-title><source>Int J Infect Dis</source><volume>37</volume><year>2015</year><fpage>77</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">26141416</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Spread of MERS to South Korea and China</article-title><source>Lancet Respir Med</source><volume>3</volume><issue>7</issue><year>2015</year><fpage>509</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">26050550</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><collab>FAO-OIE-WHO MERS Technical Working Group</collab></person-group><article-title>MERS: Progress on the global response, remaining challenges and the way forward</article-title><source>Antiviral Res</source><volume>159</volume><year>2018</year><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">30236531</pub-id></element-citation></ref></ref-list><fn-group><fn id="d32e1047"><p id="ntpara0010">Disclosures: Authors declare no conflicts of interests.</p></fn><fn id="d32e1050"><p id="ntpara0015">Author Declarations: All authors have an academic interest in coronaviruses.</p></fn><fn id="d32e1053"><p id="ntpara0020">Author Roles: All authors contributed equally to writing this article.</p></fn><fn id="d32e1056"><p id="ntpara0025">A. Zumla and C. Drosten are members of the PANDORA-ID-NET Consortium supported by a Grant RIA2016E-1609) funded by the <funding-source id="gs1">European and Developing Countries Clinical Trials Partnership</funding-source> (EDCTP2) under Horizon 2020, the <funding-source id="gs2">European Union's Framework Programme for Research and Innovation</funding-source>. A. Zumla is in receipt of a National Institutes of Health Research (NIHR) senior investigator award.</p></fn></fn-group></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001345 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001345 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7127753
|texte= The Middle East Respiratory Syndrome (MERS)
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:31668197" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |